Skip to main content

USPTO Publishes Four RNAi-Related Patent Applications: Oct 30, 2008

Premium
Title: siRNA Molecules for the Treatment of Blood Vessels
 
Number: 20080260854
 
Filed: Jan. 19, 2006 PCT Filed: Jan. 19, 2006
 
Lead Inventor: Tobias Walker, Tuebingen University
 
The invention, the patent application’s abstract states, “relates to a nucleic acid molecule, a genetic construct, siRNA molecules, and a composition [comprising those molecules that] can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a device, which is coated with the aforementioned molecules, the composition or the construct, or contains them.”
 
The abstract adds that the invention “further relates to a corresponding use of the nucleic acid molecule, of the genetic construct, or of the siRNA molecules and a method of inhibition of the expression of adhesion molecules and a method of vessel grafting, lung transplantation, treatment of lung transplants, and a method of treatment of the open heart within the scope of cardioplegia.”
 

 
Title: Methods and Compositions for Enhancing Delivery of Double-Stranded RNA or a Double-Stranded Hybrid Nucleic Acid to Regulate Gene Expression in Mammalian Cells
 
Number: 20080261304
 
Filed: Jan. 11, 2008
 
Lead Inventor: Mohammad Ahmadian, Nastech Pharmaceutical (MDRNA)
 
The patent application, its abstract states, claims “a double-stranded RNA, preferably a small interfering RNA or an siHybrid, to which cholesterol moieties are linked.”
 

 
Title: Modified Nucleosides for RNA Interference
 
Number: 20080261905
 
Filed: Nov. 8, 2005 PCT Filed: Nov. 8, 2005
 
Lead Inventor: Piet Herdewijn, University of North Carolina, Chapel Hill
 
According to the patent application’s abstract, the invention “relates to the use of modified nucleotides and single- or double-stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl, and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The … invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single- or double-stranded oligonucleotides for RNA interference, antisense therapy, or other applications.”
 

 
Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Breast Cancer
 
Number: 20080261908
 
Filed: Jan. 31, 2008
 
Lead Inventor: Carlo Croce, Ohio State University
 
The invention, the patent application’s abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.”

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.